Drug Profile
Pacritinib - CTI BioPharma
Alternative Names: ENPAXIQ; Epjevy; ONX-0803; Pacritinib citrate - CTI BioPharma; Pacritinibum; SB-1518; VONJOTMLatest Information Update: 23 Feb 2024
Price :
$50
*
At a glance
- Originator S*BIO
- Developer Cardiff University; CTI BioPharma; National Cancer Research Institute; S*BIO
- Class Antineoplastics; Aza compounds; Benzene derivatives; Ethers; Macrocyclic compounds; Polycyclic bridged compounds; Pyrimidines; Pyrrolidines; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Interleukin-1 receptor-associated kinase inhibitors; Janus kinase-2 inhibitors; Macrophage colony stimulating factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Myelofibrosis
- Phase II Graft-versus-host disease
- Discontinued Acute myeloid leukaemia; Chronic myeloid leukaemia; Colorectal cancer; Haematological disorders; Lymphoma; Myelodysplastic syndromes; Myeloproliferative disorders; SARS-CoV-2 acute respiratory disease
Most Recent Events
- 19 Dec 2023 CTI Biopharma completes a phase I drug-drug interaction trial (In volunteers) in USA (NCT05657613)
- 09 Dec 2023 Updated efficacy data from the phase III PERSIST-2 trial in Myelofibrosis presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 26 Jun 2023 CTI BioPharma has been acquired by Swedish Orphan Biovitrum